<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Langley, Ruth E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Does Aspirin's Ability to Improve CRC Prognosis Depend on PIK3CA Mutation Status?</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">Aspirin may be an effective adjuvant treatment for patients with cancer; this has been suggested by long-term follow-up of randomized trials that were originally designed to determine the vascular effects of aspirin. This article discusses Add-Aspirin, a Phase 3 double-blind multicenter trial that will determine whether taking low-dose aspirin on a regular basis will improve the prognosis of patients who have recently undergone primary curative treatment for nonmetastatic colorectal, gastroesophageal, breast, or prostate cancer.</style></abstract><number><style face="normal" font="default" size="100%">22</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>